Commitment to transparency and disclosure
Transparent reporting and disclosure play a key role in building trust with society. Novartis applies and supports laws and regulations that promote transparency around relationships between healthcare companies and healthcare professionals, healthcare organizations and patient organizations, and related transfers of value. Novartis is keeping pace with these developments and is committed to meeting new transparency requirements. Please see here for further details.
For patient organizations, Novartis goes beyond the reporting requirements set by the EFPIA (European Federation of Pharmaceutical Industries and Associations) Code of Practice. We publish a global report covering transfers of value made to patient organizations in all countries where we operate.
Novartis has supported transparency in clinical trials for more than 20 years and was one of the first companies to commit to publishing trial results of innovative medicines within one year of study completion, regardless of outcome. For more information, please see www.novartisclinicaltrials.com.